309 related articles for article (PubMed ID: 30561672)
1. PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.
Bolay FK; Grandits G; Lane HC; Kennedy SB; Johnson MP; Fallah MP; Wilson B; Njoh WS; McNay LA; Hensley LE; Higgs ES
J Infect Dis; 2019 Apr; 219(10):1634-1641. PubMed ID: 30561672
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
Kennedy SB; Bolay F; Kieh M; Grandits G; Badio M; Ballou R; Eckes R; Feinberg M; Follmann D; Grund B; Gupta S; Hensley L; Higgs E; Janosko K; Johnson M; Kateh F; Logue J; Marchand J; Monath T; Nason M; Nyenswah T; Roman F; Stavale E; Wolfson J; Neaton JD; Lane HC;
N Engl J Med; 2017 Oct; 377(15):1438-1447. PubMed ID: 29020589
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
[TBL] [Abstract][Full Text] [Related]
7. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA;
J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG;
Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Henao-Restrepo AM; Camacho A; Longini IM; Watson CH; Edmunds WJ; Egger M; Carroll MW; Dean NE; Diatta I; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Gsell PS; Hossmann S; Watle SV; Kondé MK; Kéïta S; Kone S; Kuisma E; Levine MM; Mandal S; Mauget T; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Røttingen JA; Kieny MP
Lancet; 2017 Feb; 389(10068):505-518. PubMed ID: 28017403
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
[TBL] [Abstract][Full Text] [Related]
12. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
13. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
16. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Larivière Y; Matuvanga TZ; Osang'ir BI; Milolo S; Meta R; Kimbulu P; Robinson C; Katwere M; McLean C; Lemey G; Matangila J; Maketa V; Mitashi P; Van Geertruyden JP; Van Damme P; Muhindo-Mavoko H
Lancet Infect Dis; 2024 Jul; 24(7):746-759. PubMed ID: 38552653
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
Anywaine Z; Whitworth H; Kaleebu P; Praygod G; Shukarev G; Manno D; Kapiga S; Grosskurth H; Kalluvya S; Bockstal V; Anumendem D; Luhn K; Robinson C; Douoguih M; Watson-Jones D
J Infect Dis; 2019 Jun; 220(1):46-56. PubMed ID: 30796818
[TBL] [Abstract][Full Text] [Related]
18. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
Juan-Giner A; Tchaton M; Jemmy JP; Soumah A; Boum Y; Faga EM; Cisse M; Grais RF
Vaccine; 2019 Nov; 37(48):7171-7177. PubMed ID: 30266489
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
[TBL] [Abstract][Full Text] [Related]
20. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK
Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
